These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 10731105)
1. Aromatase and breast cancer susceptibility. Probst-Hensch NM; Ingles SA; Diep AT; Haile RW; Stanczyk FZ; Kolonel LN; Henderson BE Endocr Relat Cancer; 1999 Jun; 6(2):165-73. PubMed ID: 10731105 [TBL] [Abstract][Full Text] [Related]
2. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475 [TBL] [Abstract][Full Text] [Related]
3. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Kristensen VN; Andersen TI; Lindblom A; Erikstein B; Magnus P; Børresen-Dale AL Pharmacogenetics; 1998 Feb; 8(1):43-8. PubMed ID: 9511180 [TBL] [Abstract][Full Text] [Related]
4. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Agarwal VR; Bulun SE; Leitch M; Rohrich R; Simpson ER J Clin Endocrinol Metab; 1996 Nov; 81(11):3843-9. PubMed ID: 8923826 [TBL] [Abstract][Full Text] [Related]
5. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Straume AH; Knappskog S; Lønning PE J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764 [TBL] [Abstract][Full Text] [Related]
6. Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Setiawan VW; Haiman CA; Stanczyk FZ; Le Marchand L; Henderson BE Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1849-55. PubMed ID: 17035391 [TBL] [Abstract][Full Text] [Related]
7. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women. Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193 [TBL] [Abstract][Full Text] [Related]
8. Polymorphic variation in CYP19 and the risk of breast cancer. Baxter SW; Choong DY; Eccles DM; Campbell IG Carcinogenesis; 2001 Feb; 22(2):347-9. PubMed ID: 11181459 [TBL] [Abstract][Full Text] [Related]
9. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591 [TBL] [Abstract][Full Text] [Related]
10. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Hirose K; Matsuo K; Toyama T; Iwata H; Hamajima N; Tajima K Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1407-11. PubMed ID: 15298966 [TBL] [Abstract][Full Text] [Related]
11. CYP19 (aromatase) haplotypes and endometrial cancer risk. Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924 [TBL] [Abstract][Full Text] [Related]
12. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Suspitsin EN; Grigoriev MY; Togo AV; Kuligina ES; Belogubova EV; Pozharisski KM; Chagunava OL; Sokolov EP; Theillet C; Berstein LM; Hanson KP; Imyanitov EN Eur J Cancer; 2002 Sep; 38(14):1911-6. PubMed ID: 12204674 [TBL] [Abstract][Full Text] [Related]
13. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Miller WR; Stuart M; Sahmoud T; Dixon JM Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Healey CS; Dunning AM; Durocher F; Teare D; Pharoah PD; Luben RN; Easton DF; Ponder BA Carcinogenesis; 2000 Feb; 21(2):189-93. PubMed ID: 10657957 [TBL] [Abstract][Full Text] [Related]
15. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Brueggemeier RW; Díaz-Cruz ES Minerva Endocrinol; 2006 Mar; 31(1):13-26. PubMed ID: 16498361 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421 [TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243 [TBL] [Abstract][Full Text] [Related]
18. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. Gennari L; Masi L; Merlotti D; Picariello L; Falchetti A; Tanini A; Mavilia C; Del Monte F; Gonnelli S; Lucani B; Gennari C; Brandi ML J Clin Endocrinol Metab; 2004 Jun; 89(6):2803-10. PubMed ID: 15181061 [TBL] [Abstract][Full Text] [Related]
19. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women. Ribeiro FS; de Amorim LM; de Almeida Simão T; Mendonça GA; de Moura Gallo CV; Pinto LF Toxicol Lett; 2006 Jun; 164(1):90-5. PubMed ID: 16406421 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Miyoshi Y; Iwao K; Ikeda N; Egawa C; Noguchi S Int J Cancer; 2000 Jul; 89(4):325-8. PubMed ID: 10956405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]